| 他莫昔芬与托瑞米芬治疗乳腺癌的经济学分析 |
| |
| 引用本文： | 林燕,陶红慧,严楚顺,翁乐瑾,戴佳琳. 他莫昔芬与托瑞米芬治疗乳腺癌的经济学分析[J]. 中国医院用药评价与分析, 2012, 0(4): 330-332 |
| |
| 作者姓名： | 林燕 陶红慧 严楚顺 翁乐瑾 戴佳琳 |
| |
| 作者单位： | 上海市黄浦区中心医院药剂科 |
| |
| 基金项目： | 上海市黄浦区卫生局科研项目(编号:2008-HGG-19) |
| |
| 摘 要： | 目的:评估2种内分泌治疗乳腺癌药的经济学价值。方法:130例乳腺癌患者按照不同的治疗方案分为他莫昔芬组(TAM组)80例,托瑞米芬组(TOR组)50例,观察2组治疗方案的疗效及安全性,运用药物经济学的成本-效果分析方法进行评价。结果:TAM、TOR组治疗药品成本分别为90.30、809.52元,有效率分别为88.75%、94%。结论:从药物经济学角度评估,TAM方案优于TOR方案。
|
| 关 键 词： | 乳腺癌内分泌治疗 他莫昔芬 托瑞米芬 药物经济学 |
Pharmacoeconomic Analysis on Tamoxifen vs.Toremifene for Treatment of Breast Cancer |
| |
| LIN Yan,TAO Hong-hui#,YAN Chu-shun,WENG Le-jin,DAI Jia-lin. Pharmacoeconomic Analysis on Tamoxifen vs.Toremifene for Treatment of Breast Cancer[J]. Evaluation and Analysis of Drug-Use in Hospital of China, 2012, 0(4): 330-332 |
| |
| Authors: | LIN Yan TAO Hong-hui# YAN Chu-shun WENG Le-jin DAI Jia-lin |
| |
| Affiliation: | (Dept.of Pharmacy,Shanghai Huangpu District Central Hospital,Shanghai 200002,China) |
| |
| Abstract: | OBJECTIVE:To evaluate the pharmacoeconomic value of tamoxifen versus toremifene as endocrine therapy for breast cancer.METHODS: 130 patients with breast cancer were assigned to receive either tamoxifen(group TAM,n=80 cases) or toremifene(group TOR,n=50 cases).The curative efficacy and safety of two therapies were recorded and evaluated using cost-effectiveness analysis in pharmacoeconomics.RESULTS: In TAM group versus TOR group,the drug cost stood at 90.30 yuan vs.809.52 yuan,with effective rate of 88.75% vs.94%.CONCLUSION: TAM is superior to TOR in terms of pharmacoeconomics. |
| |
| Keywords: | Endocrine therapy for breast cancer Tamoxifen Toremifene Pharmacoeconomic |
| 本文献已被 CNKI 维普 等数据库收录！ |
|
